Company: ARVN
Filing Date: 2025-08-08
Form Type: 8-K
Source: 0001655759-25-000141
Chunk: 0

Company: ARVINAS, INC.
Filing Date: 2025-08-08
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On August 8, 2025, the Company issued a press release announcing that the U. S. Food and Drug Administration ("FDA") has accepted a new drug application ("NDA") for vepdegestrant for the treatment of patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative ("HER2-") ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.